Cannabis-based medicines have incredible potential, and research is constantly showing us more areas where medical marijuana can make a difference. Now a new study out of Israel shows how the drug can be used to treat autism. Here’s why this is so big…
By now, you’re familiar with the incredible potential of cannabis-based medicine.
And as a founding member of the National Institute for Cannabis Investors, you’ve heard me talk about Epidiolex.
Epidiolex is currently only available for prescription to patients suffering from Dravet Syndrome and Lennox-Gastaut Syndrome, which are not very common. Because these forms of epilepsy did not respond to other treatments, GW Pharmaceuticals was able to gain “orphan drug” status, lowering the company’s costs and providing a window in which other drugs are not allowed to compete.
I’m glad this can help folks, but there’s much more cannabis-based medicine can do. It has the potential to treat much more than just epilepsy.
Thankfully, some states realize this and are allowing those affected with various medical conditions to access cannabis.
Depending on where you live, you may be able to obtain a medical cannabis card for conditions like:
- Multiple sclerosis
- Crohn’s Disease
- Muscle spasms
- Chronic pain
And that’s by no means an exhaustive list of conditions it could treat. Keep in mind that studying cannabis has not been easy because of its status as a Schedule 1 drug in the United States.
However, Israel has been a research powerhouse, and the country’s top scientists have found interesting results when it comes to cannabis and autism. This could be a blessing for parents and their families, and it’s one of those situations where people can be helped and you can make money.
The Clinical Research Trial
In Israel, a two-year medical study titled “Real Life Experience of Medical Cannabis Treatment in Autism; Analysis of Safety and Efficacy,” was conducted by the Soroka University Medical Center in Beersheba.
Currently, the center treats 15,000 patients with medical cannabis.
The study found that children with autism spectrum disorders (ASD) were prescribed Avidekel, a high-CBD, low-THC cannabis oil produced by Tikun Olam Ltd., the largest supplier of medical research cannabis in Israel.
Caregivers of 78 of the 188 children receiving the treatment, or 41.5% of participants, reported moderate or significant improvements.
Are ready to take your interest in cannabis investing to the next level? Our “Vault” of cannabis stocks could be your best shot at becoming a “Marijuana Millionaire.” Just click here to find out how you can get the most powerful cannabis-investing tool at your fingertips.
What’s more, before treatment began, good quality of life was reported by 31.3% of patients. At the end of the six-month study, that number jumped to 66.8%.
Reported improvements included alleviation of common ASD symptoms such as restlessness, self-injury, rage attacks, agitation, and sleep problems.
At the six-month interval, 84.6% of those patients reported a complete disappearance of seizure symptoms, 91% reported improvement with restlessness, and 90.3% reported improvement with rage attacks.
These are great results, and they could mean big things for increasing cannabis as a medical solution.
For one, this study gives Big Pharma another reason to shake in its boots.
That’s because 20% of participants who used anti-psychotic drugs at the outset of the study had completely stopped using those medications after the six-month follow-up.
Time and time again, we’re seeing the potential of cannabis to displace huge portions of the pharmaceuticals industry.
Of course, there’s still a little way to go before that happens, which means there’s still a lot of big money to be made here. We still need to see less restrictive cannabis laws so scientists can study it.
But the results from this study are promising.
Dr. Gal Mieri, head of the Preschool Psychiatry Unit at Soroka Medical Center and co-author of the study, said, “We plan to collect data about children with ASD and their families from all over Israel in order to have bigger studies about risk factors to autism and possible treatments.”
“Meanwhile,” Mieri said, “this study gives hope to autism patients for safe treatment and relief for some of their most difficult symptoms.”
Na’ama Saban is a registered nurse and another co-author of the study. She added to Mieri’s optimism, saying, “With the advancements made in therapy and the accumulated knowledge that was acquired during this study, I am confident further research will deepen our understanding and help us improve treatment as best and as precisely as possible.”
Those who know how to position themselves now and understand that cannabis-based medicine is more than just a trend will have the potential to make the most money from the right investments.
Thanks for being an integral part of the National Institute for Cannabis Investors,
Executive Director, National Institute for Cannabis Investors
P.S. One of the most exciting things our paid-up National Institute for Cannabis Investors members get to enjoy is learning how to become a successful angel investor in privately held cannabis startups. In America, Angel Investing used to be something that only the wealthiest 2% could take part in. But this has been gradually changing over the years. As a member, we’re going to show you all of the ins and outs of this lucrative opportunity. In fact, we even have the details on a unique opportunity already locked and loaded for you. Just click here to find out how you can get in on the action.
10 responses to “A New Condition for Medical Cannabis Treatment”
February 25 2019